Evidence map›Paper›PMID 42909883›Full record

ArticleInternational journal of biological sciences2026

Exon-6 truncated p53 Suppresses Innate Immune Responses to Facilitate Immune Evasion in Bladder Cancer.

Chi Zhang, Wenjie Wei, Senming Cao, Zhi Li, Chuang Wang, Wen Tao, Yuhao Dong, Chunyu Liu, Shun Wu, Shuo Tian and 6 more

Abstract read
In one paragraph

Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Chi ZhangSenior Department of Urology, Chinese PLA General Hospital, Beijing, China.
Wenjie WeiDepartment of Urology, The Affiliated Hospital of Qingdao University, Qingdao, 266000, China.
Senming CaoSenior Department of Urology, Chinese PLA General Hospital, Beijing, China.
Zhi LiSchool of medicine, Nankai University, Tianjin, 300071, China.
Chuang WangSchool of medicine, Nankai University, Tianjin, 300071, China.
Wen TaoSchool of medicine, Nankai University, Tianjin, 300071, China.
Yuhao DongSchool of medicine, Nankai University, Tianjin, 300071, China.
Chunyu LiuSchool of medicine, Nankai University, Tianjin, 300071, China.
Shun WuSchool of medicine, Nankai University, Tianjin, 300071, China.
Shuo TianSchool of medicine, Nankai University, Tianjin, 300071, China.
Qingbo HuangSenior Department of Urology, Chinese PLA General Hospital, Beijing, China.
Baojun WangSenior Department of Urology, Chinese PLA General Hospital, Beijing, China.
Hongzhao LiSenior Department of Urology, Chinese PLA General Hospital, Beijing, China.
Xin MaSenior Department of Urology, Chinese PLA General Hospital, Beijing, China.
Xu ZhangSenior Department of Urology, Chinese PLA General Hospital, Beijing, China.
Yan HuangSenior Department of Urology, Chinese PLA General Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous studies have reported that truncated p53 exhibits pro-tumorigenic properties; however, whether it contributes to immune evasion by influencing the immune microenvironment remains unclear. Here, we report that exon-6-truncated p53 isoforms (E6-trunc p53) inhibit type I interferon (IFN-I) signaling, thereby supporting tumor cell survival and enabling immune evasion. Ectopic expression of E6-trunc p53 reduces T-cell infiltration into tumors and markedly promotes

Indexed as

Immune EvasionImmunity, InnateTumor Suppressor Protein p53Urinary Bladder NeoplasmsAnimalsCell Line, TumorExonsHumansInterferon Type IMiceProtein Serine-Threonine KinasesSignal TransductionInterferon Type IProtein Serine-Threonine KinasesTBK1 protein, humanTumor Suppressor Protein p53bladder cancer immunotherapy responseimmune evasioninnate immunetruncated p53type I interferon

Identifiers

PMID42909883
PMCPMC13685605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.